



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : A61F 2/00, 2/02	A1	(11) International Publication Number: WO 92/07525 (43) International Publication Date: 14 May 1992 (14.05.92)
(21) International Application Number: PCT/US91/07486 (22) International Filing Date: 10 October 1991 (10.10.91) (30) Priority data: 606,791 31 October 1990 (31.10.90) US 735,401 24 July 1991 (24.07.91) US (71) Applicant: BAXTER INTERNATIONAL INC. [US/US]; One Baxter Parkway, Deerfield, IL 60015 (US). (72) Inventors: BRAUKER, James, H. ; 307 Marengo Road, Harvard, IL 60033 (US). JOHNSON, Robert, C. ; 722 Hackberry Court, Bartlett, IL 60103 (US). MARTIN- SON, Laura, A. ; 25188 W. Entrance Drive, Lake Villa, IL 60046 (US). HILL, Ronald, S. ; 627 Stuart St., Grays- lake, IL 60030 (US).		(74) Agents: BATES, Sarah, E. et al.; One Baxter Parkway, Deerfield, IL 60015 (US). (81) Designated States: AT (European patent), AU, BE (Euro- pean patent), BG, BR, CA, CH (European patent), CS, DE (European patent), DK (European patent), ES (Eu- ropean patent), FI, FR (European patent), GB (Euro- pean patent), GR (European patent), HU, IT (European patent), JP, KR, LU (European patent), MC, NL (Euro- pean patent), NO, PL, RO, SE (European patent), SU ⁺ . Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the</i> <i>claims and to be republished in the event of the receipt of</i> <i>amendments.</i>
(54) Title: CLOSE VASCULARIZATION IMPLANT MATERIAL (57) Abstract <p>A device for implantation in a host having a material at an interface between the host and the device, said material having a conformation which results in growth of vascular structures by the host close to the interface.</p>		

+ DESIGNATIONS OF "SU"

Any designation of "SU" has effect in the Russian Federation. It is not yet known whether any such designation has effect in other States of the former Soviet Union.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	MG	Madagascar
AU	Australia	FI	Finland	ML	Mali
BB	Barbados	FR	France	MN	Mongolia
BE	Belgium	GA	Gabon	MR	Mauritania
BF	Burkina Faso	GB	United Kingdom	MW	Malawi
BG	Bulgaria	GN	Guinea	NL	Netherlands
BJ	Benin	GR	Greece	NO	Norway
BR	Brazil	HU	Hungary	PL	Poland
CA	Canada	IT	Italy	RO	Romania
CF	Central African Republic	JP	Japan	SD	Sudan
CG	Congo	KP	Democratic People's Republic of Korea	SE	Sweden
CH	Switzerland			SN	Senegal
CI	Côte d'Ivoire	KR	Republic of Korea	SU ⁺	Soviet Union
CM	Cameroon	LI	Liechtenstein	TD	Chad
CS	Czechoslovakia	LK	Sri Lanka	TG	Togo
DE	Germany	LU	Luxembourg	US	United States of America
DK	Denmark	MC	Monaco		

- 1 -

CLOSE VASCULARIZATION IMPLANT MATERIAL

Background of the Invention

The present invention relates to material implanted in a host. More particularly, the present invention relates to material that promotes the formation of vascular structures at the interface between at least a portion of the implanted material and the host.

For a variety of applications, ranging from research to therapeutic, it may be desirable to implant an article or device within soft tissue. Such implants can include indwelling catheters, indwelling sensors, and devices for holding tissue that are implanted in vivo.

If the implanted device is utilized to hold tissue, in a variety of such applications it is necessary to isolate the implanted tissue from the immune response of the host (immunoisolation). For example, this is critical when the
20 implanted tissues are xenografts, i.e., graft cells from donors of another species, or allografts, i.e., cells from the same species but having a different genetic make-up. A failure to properly isolate such tissue will result in an invasion from host cells or host immunogenic factors rejecting the implant cells. In certain
25 other applications, such as autografts, i.e., cells previously isolated from the tissue of the patient to be implanted, it is necessary to isolate the implanted tissues from the host, not because the cells would be rejected, but because the cells may contain retroviral vectors which otherwise might present a risk to
30 the patient. Accordingly, it may be necessary for such cells to be enclosed within a structure that prevents the passage of cells therethrough.

- 2 -

In certain other implant applications it may be desirable to provide a zone or structure that is selectively impermeable for molecular diffusion as in certain forms of cellular implants that could be rejected by humoral factors, or non-permeable for non-transport functions, such as providing a surface for transcutaneous catheters.

When biomaterials are implanted, the host inflammatory cells (macrophages, giant cells, and fibroblasts) produce an inflammatory response called a foreign body response. This response invariably results in a zone of nonvascular tissue that surrounds the implanted material. The foreign body response is the body's attempt to remove or isolate the foreign entity (Anderson, J. M., "Inflammatory Response to Impants", Trans. Am. Soc. Artif. Interm. Ograns, Vol. XXXIV:101-107 (1988)).

During the foreign body response, macrophages from the host attempt to ingest the foreign body. In some cases, the macrophages coalesce to form multinucleated giant cells. The implant may lead to the formation of fibroblast layers of increased thickness and density as the host attempts to isolate the foreign body. This creates a fibrous capsule of cells and collagen.

Referring to Figure 1, a micrograph (1(a)) and a drawing (1(b)) are provided to illustrate a classical tissue response to an implanted foreign body. Figure 1 represents a typical histological section taken through a tissue block removed after approximately three weeks from a dorsal subcutaneous implant in a Sprague-Dawley rat. As illustrated, the implant 10 is surrounded by a foreign body capsule 12 that forms adjacent to the implant. The foreign body capsule 12 typically consists of three-layers.

As illustrated, the first layer 13 of the foreign body capsule 12 includes macrophages 14 and foreign body giant cells 16 at an interface 18 between the implant 10 and the tissue. This first layer 13, consisting of the macrophages 14, is generally approximately 5 to about 15 microns thick.

- 3 -

5 The next, or second layer 15, of the foreign body capsule 12 includes fibroblasts 20. The fibroblasts 20 are oriented parallel to the surface of the implant 10 and embedded in a collagenous matrix including collagen fibers that are also oriented parallel with the surface of the implant. The second layer 15 consisting of the fibroblasts 20 and collagen fibers is generally approximately 30 to about 200 microns thick. The first and second layers 13 and 15 of the foreign body capsule 12 are usually completely avascular throughout.

10 At the outlying areas of the foreign body capsule 12, a few vascular structures 24 begin to appear in the outer regions of the fibroblast second zone 15. At a third layer 17, lying approximately 30 to about 200 microns away from the surface of the implant 10 is loose connective tissue that is highly vascular.
15 This layer 17 is amorphous and widely varies in thickness depending on the tissue location and time after the implant.

As illustrated in Figure 1, the classical foreign body response results in the implant 10 being surrounded by a foreign body capsule 12 that does not include vascular structures near the
20 surface of the implant.

Although the foreign body capsule generated from the foreign body response is desirable, or at least not detrimental, for certain types of implants, such as, for example, silicon breast implants and collagen implants, the foreign body capsule prevents
25 certain applications and treatments utilizing such implants. For example, indwelling sensors for applications such as glucose analysis in diabetics, become occluded after only a few days due to the foreign body capsule. Indeed, the foreign body capsule becomes so thick that it inhibits the diffusion of glucose to the
30 membrane surface preventing the sensor from functioning.

Likewise, when pancreatic islets are implanted within a semipermeable membrane for treatment of diabetes, they usually die within a few days or weeks. The loss of function of the

- 4 -

pancreatic islets is attributed to the poor diffusion of nutrients to the islets due to the thickness of the foreign body capsule. Likewise, other tissues that are implanted within the host do not remain viable due to the foreign body capsule that effectively prevents the transport of nutrients from the capillaries to cells enclosed within the implanted membrane.

Scharp, in a comprehensive review of the literature about immunoisolation ("Isolation and Transplantation of Islet Tissue" (1984) World J. Surgery 8:143-151) cited 18 papers on islet immunoisolation. In every case, the islets failed to function for more than a few weeks, or in 4 studies, several months. In every case but one, the failure was attributed to fibroblastic overgrowth of the membrane and chamber. The authors state that, "If...a [membrane] can be constructed to resist host fibrotic response, then the extravascular diffusion chamber approach may be useful clinically." They further state that the "primary disadvantages [of diffusion chambers] relate to the host fibroblastic response to the device." This belief is echoed in U.S. Patent No. 4,298,002 which states, "the device...remains effective for limited periods of time because the body encapsulates the device with fibrous material blocking the passage of insulin, nutrients, and/or waste products."

More recent papers continue to state that device failure is caused by the foreign body capsule diminution of diffusion. For example, Christenson, Abeischer, McMillan, and Galletti, in "Tissue Reaction to Intraperitoneal Polymer Implants: Species difference and effects of corticoid and doxorubicin" ((1989) J. of Biomed. Mat. Res. 23:705-718) stated, "reduction of the tissue reaction around an implant is important in improving the long-term viability of the encapsulated endocrine tissue and is imperative for any clinical application of this technique for implanting endocrine tissue."

- 5 -

Poor viability of tissues has prompted the design of modalities for periodic replacement of implanted islets through percutaneous catheters (e.g. U.S. Patent No. 4,378,016) to solve the shortcoming of previous designs, i.e., the deterioration of implanted tissues because of overgrowth by a fibrous capsule.

Additionally, indwelling catheters that have a variety of applications, typically have a high drop-out rate because the site of the catheter entry becomes infected. It is generally believed that this infection is caused by poor adhesion of the tissues to the catheter surface and poor vascularization of the region around the catheter because of the thick foreign body capsule that forms. Implants have been proposed having surfaces designed to increase the adhesion or anchorage of the implant in the host tissue (e.g. European Patent Application No. 0359575 of Von Recum and Campbell). This patent application describes materials with surface topography designed to provide "improved soft tissue implant having a surface texture that optimizes anchorage of the implant to the tissue without causing inflammatory tissue at the implantation site."

In attempting to provide needed nutrients to cells and tissues located within implanted devices and/or allowing agents generated by the tissues to enter the host, an almost contradictory concern must be dealt with. For devices that include xenografts or allografts, these tissues must be isolated from the immune system of the host. Therefore, although it may be desirable to somehow connect the vascular system of the host to these tissues to provide nutrients and allow a transfer of biological agents to the host, a contrary concern is to prevent an immune response from the host to the tissues. Likewise, with respect to sensors and catheters, although it may be desirable to create vascularization with respect to these devices, vascularization into an interior of such devices will prevent the devices from functioning satisfactorily.

- 6 -

Summary of the Invention

This present invention provides an implant material that results in close vascularization by the host at the interface between the material and the host into which the material is
5 implanted.

The uses of the material of the present invention include: as a coating for indwelling catheters; means for transport of physiological factors to indwelling sensors; means for transport of drugs from a chamber or catheter to the tissues of the host;
10 and means for encapsulation of grafted cells for treatment of cell and molecular deficiency diseases (immunoisolation).

In an embodiment, the present invention provides an asymmetric material having a first zone that induces close vascularization at the material host interface and a second adjacent zone that
15 prevents passage of cells through the zone. The vascularizing zone allows the material to be vascularized while the second zone maintains immunoisolation of the interior of an implanted device incorporating the invention on its exterior. The material may consist of a bilayer of zones as described or it may be a gradient
20 of zones. The gradient consists of an outer zone with a conformation that results in close vascularization. The structure of the material becomes gradually tighter until the material is impermeable to cells.

In another embodiment, the second adjacent zone is molecular permeable for selective diffusion. In yet another embodiment the
25 second zone is non-permeable for use in non-transport functions in devices such as indwelling catheters.

To these ends, the present invention provides an implant having a three dimensional conformation or architectural structure
30 at the host interface which allows invasion of the material by mononuclear cells, but prevents the invasion by connective tissue which leads to foreign body capsule formation within the structure.

Applicants do not fully understand how the close vascularization of the present invention occurs. The data

- 7 -

presented in the tables and figures which follow are consistent with the theory that close vascularization occurs if the three dimensional conformation of material interfacing the host is such that it elicits certain host inflammatory cell behavior.

5 Applicants have observed by light and electron microscopy that close vascularization occurs if in the initial period of implantation, at least some macrophages entering the material are not activated. Activated macrophages are characterized by cell flattening. Applicants observe close vascularization in regions

10 of an implant where the macrophages that have entered the cavities of the material retain a rounded appearance when viewed through light microscopy ($\sim 400\times$). See Figure 2a. At $3000\times$ (TEM) the rounded macrophage is observed to have substantially conformed to the contours of the material. Although there is a

15 correlation with macrophage shape, it is not clear that macrophages control the observed response. However, it is clear that invasion of the structure by host cells is required. Although the bulk of the cells appear to be macrophages, it is possible that other inflammatory cells control the response,

20 therefore we will refer to the invading cells as "inflammatory cells," which include but are not limited to macrophages.

On the other hand foreign body capsule formation occurs when, in the initial period of implantation, inflammatory cells in contact with the implant material flatten against those portions

25 of the material which present an area amenable to such flattening behavior by an inflammatory cell (Figure 6).

In an embodiment, the material that results in formation of close vascular structures is a polymer membrane having an average nominal pore size of approximately 0.6 to about $20\text{ }\mu\text{m}$, using

30 conventional methods for determination of pore size in the trade. Preferably, at least approximately 50% of the pores of the membrane have an average size of approximately 0.6 to about $20\text{ }\mu\text{m}$.

- 8 -

The structural elements which provide the three dimensional conformation may include fibers, strands, globules, cones or rods of amorphous or uniform geometry which are smooth or rough. These elements, hereafter referred to as "strands," have in general one dimension larger than the other two and the smaller dimensions do not exceed five microns.

In an embodiment, the material consists of strands that define "apertures" formed by a frame of the interconnected strands. The apertures have an average size of no more than about 20 μm in any but the longest dimension. The apertures of the material form a framework of interconnected apertures, defining "cavities" that are no greater than an average of about 20 μm in any but the longest dimension. In an embodiment the material has at least some apertures having a sufficient size to allow at least some vascular structures to be created within the cavities. At least some of these apertures, while allowing vascular structures to form within the cavities, prevent connective tissue from forming therein because of size restrictions.

In an embodiment, an asymmetric material is provided having a gradient or layer of varying porosity. At least some of the apertures at the surface of the material that contacts the host tissue, allow inflammatory cells to enter the cavities. But, due to size restrictions, the apertures do not allow the inflammatory cells to transverse the material to the interior of the implant.

In an embodiment of the present invention, an immunoisolation container is provided that includes a first membrane having cavities and situated proximal to the host tissue. At least some of the apertures of the first membrane have a sufficient size to allow inflammatory cells to enter the cavities and cause at least some vascular structures to contact the membrane. The container includes a second porous membrane, the apertures of the second membrane being sufficiently small to prevent immune cells and/or immunogenic factors from entering an interior of the container. The second membrane is situated proximal to graft tissues.

- 9 -

In an embodiment, an indwelling catheter is provided by the present invention including a porous membrane and a catheter body, the porous membrane surrounding at least a portion of the catheter body. At least some apertures of the porous membrane have a
5 sufficient size to allow inflammatory cells to enter the cavities and cause at least some vascular structures to form that contact the porous membrane.

In an embodiment, the present invention provides an indwelling sensor. The indwelling sensor comprising a sensor for monitoring
10 a condition or agent in the body and a porous membrane that surrounds at least a portion of the sensor body. At least some of the apertures of the membrane have a sufficient size to allow inflammatory cells to enter the cavities and cause at least some vascular structures to form that contact the porous membrane.

15 The present invention also provides a method for the vascularization of a surface of an implanted device. The method comprises the steps of allowing inflammatory cells to enter a first layer of a membrane structure and cause vascular structures to form that contact a surface of the first layer of the membrane
20 and preventing the inflammatory cells from entering a second layer of the membrane structure. This embodiment would be applicable in, for example, a breast prosthesis.

Additional features and advantages of the present invention are described in, and will be apparent from, the detailed
25 description of the presently preferred embodiments and from the drawings.

Brief Description of the Drawings

Figure 1(a) is a micrograph that illustrates a classical
30 foreign body response to an implanted device.

Figure 1(b) is a drawing illustrating a classical foreign body response to an implanted device.

Figure 2(a) is a micrograph of an embodiment of the present invention.

- 10 -

Figure 2(b) is a cross-sectional view of an embodiment of the present invention with vascular structures growing at the host-material interface.

5 Figure 3 illustrates a cross-sectional view of a foreign body capsule in a pore of a membrane.

Figures 4(a) and (b) are scanning electron micrographs of, respectively, a mixed ester of cellulose membrane with a 5 μm pore size and a teflon membrane with 3 μm pore size.

10 Figures 5(a) and (b) are scanning electron micrographs of, respectively, a teflon membrane with a 5 μm pore size and a polycarbonate with 12 μm pore size.

Figure 6 illustrates a light micrograph showing the teflon membrane of Figure 5(a) implanted for 3 weeks in a subcutaneous dorsal pocket in a rat.

15 Figure 7 illustrates a cross-sectional view of a bilaminar membrane containing islets, the membrane having an outer layer that is vascularized and an inner layer that prevents immune rejection.

20 Figure 8 illustrates a cross-sectional view of a further embodiment of the present invention.

Figure 9 illustrates an indwelling catheter incorporating the present invention.

Figure 10 illustrates an indwelling sensor incorporating the present invention.

25

Detailed Description of the Presently Preferred Embodiments

30 The present invention provides a material for inducing close vascularization at the interface between the material and host into which the material is implanted such that a standard foreign

- 11 -

body capsule consisting of flattened macrophages, foreign body giant cells, and fibroblasts does not intervene between the vascular structures and the material. The material can be utilized for various applications including the creation of a container for implanting tissues to be isolated from the immune system of a host, for surrounding a portion of a catheter, or surrounding a portion of an indwelling sensor device.

Pursuant to the present invention, the material utilized results in the growth of vascular structures close to or immediately adjacent to the material. As used herein, close vascular structures or vascular structures that contact, are those capillaries whose surface lies within about one cell layer of the surface of the material. When implants including the materials of the present invention are implanted within a host a foreign body-like capsule still forms in response to the implantation. However, its structure is greatly altered due to the host response to the material. In contrast to a standard foreign body response, a vascular bed forms at the host-material interface.

Referring now to Figure 2, an embodiment of the present invention is illustrated. In this embodiment, a polymer membrane 30 at least partially surrounds an implant and includes three dimensional cavities 32. At least some of the cavities 32 of the membrane 30 have a sufficient size and structure to allow inflammatory cells 34 to completely enter therein through the apertures that define the cavities, and are defined by frames composed of strands that are less than five microns in all but the longest dimension. When the inflammatory cells 34 enter the cavities 32, growth of vascular structures 36 occurs within about one cell layer from the interface 35 of the membrane 30 and host. Although not required, vascular structures may be formed within the irregularities 32 of the membrane. Accordingly, although a foreign body-like capsule of fibroblasts still forms that surrounds the membrane 30, the entire foreign body-like capsule,

- 12 -

including fibroblast layers, is well vascularized. The formation of close vascular structures is dependent on entry of the inflammatory cells into the cavities of the membrane so that the cells are surrounded by the strands that define the apertures and cavities. The topographic features at the implant surface do not effect the morphology of the inflammatory cells. Indeed, inflammatory cells at the implant surface often maintain a flat morphology.

In selecting the size and shape of the strands and cavities 32 for the material 30 of the present invention, it must first be appreciated that not all of the cavities must have a sufficient size to allow inflammatory cells 34 to enter therein. What is required is that a sufficient number of cavities 32 have a size that allows a sufficient number of inflammatory cells 34 to enter therein. Nor is it necessary that all of the strands be less than five microns in all but the longest dimension. Some strands may be longer, as long as a sufficient number of the strands are within the prescribed size limits. The presence of a sufficient number of strands and cavities of the prescribed size creates a sufficient number of vascular structures at the host-material interface. These vascular structures will provide sufficient nutrients to an immunoisolated container and/or allow components and agents produced by cells within the interior of the chamber to enter the host.

Although at least some of the cavities 32 must have a sufficient size and shape to allow inflammatory cells 34 to enter therein, it is also important that extensive ingrowth of vascular and connective tissues within the cavities 32 does not occur. As illustrated in Figure 3, in the case where the apertures and cavities are too large, an extensive growth of vascular tissue 36 and connective tissue 39 occurs within a large cavity 32a; this causes the vascular tissue to be isolated within the large cavity. The isolation of the vascular tissue 36 within the large

- 13 -

cavity 32a by fibroblasts and connective tissues 39 is similar to the standard foreign body response previously discussed. By selecting cavities 32 of appropriate size, one can prevent the formation of fibroblasts and connective tissue 39 therein.

5 It has been found that a porous polymer membrane having an average nominal pore size of approximately 0.6 to about 20 microns and average strand sizes of less than about five microns in all but the longest dimension, functions satisfactorily in creating a
10 vascular bed at the tissue-membrane interface. It should be noted, that the term "nominal pore size" is derived from methods of analysis common to the membrane trade, such as the ability of the membrane to filter particles of a particular size, or the resistance of the membrane to the flow of fluids. Because of the amorphous, random and irregular nature of most of these
15 commercially available membranes, the "pore" size designation does not actually indicate the size or shape of the apertures and cavities, which in reality have a high degree of variability. The cavities are not really "pores" in that they typically are not uniform regular holes or channels through the material. Instead,
20 these commercial membranes can be composed of, for example, extruded filaments which act as sieves as shown, for example, in Figure 4b. Accordingly, as used herein the term "pore size" is a manufacturer's convention used to identify a particular membrane of a particular commercial source which has a certain bubble
25 point. As used herein, the term "pore" does not describe the size of the cavities of the material used in the instant invention. The bubble point measurement is described in Pharmaceutical Technology May 1983 pp. 36 to 42.

30 As previously noted, it is not critical that all of the apertures 32 (Fig. 2) of the material 30 allow inflammatory cells 34 to penetrate the material or, conversely prevent connective tissues from forming within the cavities. What is required is that a sufficient number of the cavities 32 have a size that

- 14 -

allows inflammatory cells 34 to enter therein and yet prevent connective tissue from forming therein. In the materials tested by Applicants the desired result is obtained where the strands that define the apertures of the cavities have a size of less than about five microns in all but the longest dimension. It has been determined that a commercially available membrane having at least approximately 50% of its cavities with an average nominal size of approximately 0.6 to about 20 microns and strands having an average size of less than about five microns in all but the longest dimension will function satisfactorily in creating vascular structures close to the membrane.

By way of example, and not limitation, the following experiments were performed on commercially available membranes to determine which membranes result in the close vascularization of the present invention.

Numerous commercially available membranes with varying nominal pore sizes were implanted in subcutaneous pockets on the backs of adult male Sprague Dawley rats for three weeks, and examined histologically. The results, shown in Tables 1-3, were that all membranes with apertures too small or having strands too closely associated to allow penetration of macrophages (Table 1) had standard foreign body capsules (i.e., similar to that illustrated in Figure 1), whereas many membranes with apertures large enough to allow macrophages to penetrate (Table 2) had close vascular structures (i.e., similar to that illustrated in Figure 2).

- 15 -

TABLE I
MEMBRANES THAT ARE NOT INVADED BY CELLS AND
DO NOT HAVE CLOSE VASCULAR STRUCTURES

	<u>Company</u>	<u>Membrane</u>	<u>Nominal Pore Size</u>
	Millipore	Mixed Esters Cellulose	0.1
	Millipore	Mixed Esters Cellulose	0.22
5	Millipore	Mixed Esters Cellulose	0.45
	Celenase	polypropylene	0.05
	Celenase	polypropylene	0.075
	Gore	PTFE/Polyester	0.02
	Gore	PTFE/Polyester	0.2
10	Akzo	polypropylene	0.01-0.29
	Akzo	polypropylene	0.02-0.58
	Akzo	polyethylene	0.1
	Akzo	polyethylene	0.08
	Akzo	polyethylene	0.6
15	Supor	polysulfone	0.1
	Amicon	YC, YM, PM, XM	10-300 kD
	Omega	polyethersulfone	100-300kD
	Millipore	Durapore®	0.22
	Millipore	Immobilon-n®	0.22
20	Gelman	Versapore®	0.22
	Gelman	Supor®	0.22
	Gelman	Supor®	0.8
	Gelman	Polysulfone HT-200	0.22
	Gelman	Polysulfone HT-200	0.6
25	Gelman	Polyester	0.22
	Gelman	Polysulfone/polyester	0.8
	Sartorius	Cellulose Acetate	0.22
	Sartorius	Cellulose Acetate	0.22
	Sartorius	Cellulose Acetate	0.45
30	Sartorius	Cellulose Acetate	0.65
	Sartorius	Cellulose Nitrate	0.22
	Sartorius	Reinforced Cell. Acet.	0.22
	Nucleopore	Polyester	0.8

- 16 -

TABLE I

(Continued)

MEMBRANES THAT ARE NOT INVADED BY CELLS AND
DO NOT HAVE CLOSE VASCULAR STRUCTURES

5			
	<u>Company</u>	<u>Membrane</u>	<u>Nominal</u>
	Pall	Uncharged Nylon	<u>Pore Size</u>
	AMF Cumo	Charged Nylon	0.22
10	Micron Separation	Nylon 66	0.22
	Inc.		
	Micro Filtration	Cellulose Acetate	0.22
	Sys.		
	Micro Filtration	Cellulose Acetate	0.22
15	Sys.		
	Akzo	Polypropylene-HF	0.2-0.8

20

25

30

- 17 -

TABLE 2MEMBRANES THAT ARE INVADED BY CELLS
AND HAVE CLOSE VASCULAR STRUCTURES

5			Nominal
	<u>Company</u>	<u>Membrane</u>	<u>Pore Size</u>
	Millipore	Mixed Esters Cellulose	1.2
	Millipore	Mixed Esters Cellulose	8.0
10	Sartorius	Cellulose Acetate	0.8
	Sartorius	Cellulose Acetate	1.2
	Sartorius	Cellulose Acetate	3.0
	Sartorius	Cellulose Acetate	5.0
	Sartorius	Cellulose Acetate	8.0
15	Gore	PTFE/Polyester	1.0
	Gore	PTFE/Polypropylene	3.0
	Gore	PTFE/Polyester	3.0
	Gelman	Versapore®	0.8
	Gelman	Versapore®	1.2
20	Gelman	Versapore®	3.0
	Gelman	Versapore®	5.0
25			
30			

- 18 -

TABLE 3

MEMBRANES THAT ARE INVADED BY CELLS
BUT DO NOT HAVE CLOSE VASCULAR STRUCTURES

5			Nominal
	<u>Company</u>	<u>Membrane</u>	<u>Pore Size</u>
	Tetco	Polyester	3
	Tetco	Polyester	5
10	Tetco	Polyester	8
	Tetco	Nylon	10
	Tetco	Nylon	10
	Tetco	Nylon	10
	Millipore	PTFE	5
15	Millipore	PTFE	10
	Nucleopore	Polycarbonate	1
	Nucleopore	Polycarbonate	3
	Nucleopore	Polycarbonate	8
20	Nucleopore	Polycarbonate	12

25

30

- 19 -

For example, membranes created from mixed esters of cellulose and having nominal pore sizes of 0.1, 0.22, and 0.45 microns did not induce close vascular structures when subcutaneously implanted into rats. However, mixed esters of cellulose membranes with nominal pore sizes of 1.2 and 8 microns did induce close vascular structures. Similarly, cellulose acetate membranes having a nominal pore size of 0.2, 0.45, and 0.65 microns and teflon membranes having a nominal pore size of 0.02 and 0.2 microns did not induce close vascular structures. But, cellulose acetate membranes having a nominal pore size of 0.8, 1.2, 3, 5, and 8 microns, and teflon membranes having a nominal pore size of 1.0 and 3.0 microns did induce close vascular structures.

In membranes wherein close vascular structures were seen, the membrane was penetrated by inflammatory cells from the host. It is believed that the formation of close vascular structures is related to cellular invasion. However, numerous membranes that did allow penetration of inflammatory cells did not have close vascular structures (Table 3), indicating that invasion by inflammatory cells was perhaps related, but, not necessarily sufficient for the production of close vascular structures.

Scanning Electron Microscope (SEM) analysis of the membranes revealed three dimensional structural or architectural properties that distinguish membranes that do have close vascular structures (positive response) from those that do not (negative response). Membranes with a positive response had high porosities and were composed of strands (fibers, filaments, microglobules, cone-like or rod-like structures with a small diameter (< 5 microns)). For example, Millipore brand mixed esters of cellulose membranes with nominal pore size of 5 μm are composed of irregular, amorphous globular structures and strands with diameters from about 1 to 3 μm , and irregular cavities from 0.5 to 5 microns in diameter, and having a percent porosity of 75% (Figure 4a). Gore® teflon membranes with a nominal pore size of 3 μm are composed of strands with diameters of less than about 1 micron that interconnect with

- 20 -

teflon clusters less than about 3 microns in diameter (Figure 4b). The cavities are very elongated being generally about 1 to 2 microns wide by 10 to 15 μ m long. After implantation, both of these membranes were invaded by inflammatory cells which had a round morphology under the light microscope (see invading cells in Figure 2), and both consistently had close vascular structures.

In contrast, membranes with a negative response had apertures and cavities defined by strands with a relatively high surface area, large enough for inflammatory cells to use as a substrate to flatten against. For example, Millipore brand teflon membranes with a nominal pore size of 5 microns (Figure 5a) are composed of globular or plate-like structures about 5 to 10 microns in diameter, and have irregular amorphous cavities about 5 to 10 microns in diameter. Nuclepore brand membranes with a nominal pore size of 12 microns (Figure 5b), have uniform circular holes that are 9 microns in diameter that are scattered within a membrane sheet, with from 5 to 25 microns between the edges of the holes. After implantation, both of these membranes were invaded by cells but the cells maintained a flattened morphology (see invading cells in Figure 6).

Thus, the three dimensional conformation or architecture of the structures that delimit the cavities and irregularities have a strong influence on the biological response.

Applicants have further determined that materials with a positive response had structural features that caused penetrating cells to assume a round morphology. Whereas materials with a negative response had structural features that caused penetrating cells to assume a relatively flattened morphology.

Membranes with a negative response have a standard foreign body capsule after implantation, and were invaded by inflammatory cells that assumed an elongated, highly flattened morphology (Figure 6). Figure 6 is a light micrograph illustrating a teflon membrane (the same membrane illustrated in Figure 5a) implanted for 3 weeks

- 21 -

in a subcutaneous dorsal pocket in a rat. Note the extensive cytoplasm of the cells invading the polytetrafluoroethylene ("PTFE") membrane shown in Figure 6. The cells appear to have flattened against the plate-like PTFE structure and have the appearance of cells of a standard foreign body response (Figure 1) in contrast to the rounded cells invading the membrane in Figure 2.

This is consistent with the observation of rounded mononuclear cells invading an implant during the early, acute phase of a foreign body response, followed by flattened cells on the surface of implants in the later, chronic standard foreign body response to implants with a smooth surface (e.g., Figure 1). The flattening of the macrophages and foreign body giant cells against the surface walls off the implant, is followed by a quiescent, chronic response characterized by a lack of new invading mononuclear cells and a lack of new vascular growth in the periphery of the foreign body. Macrophages and foreign body giant cells from the initial host reaction to the implant remain, but are generally flattened against the foreign material. This is a long-term response that results in a permanent walling off of implants that are non-digestible by the macrophage. The maintenance of a long-term foreign body response is characterized by inflammatory cells which spread upon and cover the foreign material. Applicants have discovered that this response appears to require a surface-like area capable of acting as a substrate for flattening and spreading of the cells.

When the implanted material has an architecture of strands that have a diameter ($< 5 \mu\text{m}$) too small or configuration too irregular to allow a surface for flattening of cells, as do the membranes that give a positive vascular response (Figure 2 and Table 2), the efforts of the inflammatory cells to cover and wall off the material are thwarted, and the cells do not obtain a flattened morphology. Instead, they remain rounded and Applicants hypothesize that the inflammatory cells induce the formation of

- 22 -

close vascular structures at the material-host interface. The implanted material is never completely walled off, and therefore a chronic response is never obtained.

5 Flattening and activation of inflammatory cells (which leads to foreign body capsule formation) is observed where the implant material provides a structure onto which the inflammatory cells can flatten and spread. An inflammatory cell does not require a smooth area for flattening. For example, an area composed of
10 closely adjacent pillars of equal height and diameter might be recognized by the inflammatory cell as essentially "smooth" and the cells would then spread on the surface.

Applicants further hypothesize that if the inflammatory cell nucleus cannot enter a cavity or irregularity then the cell will "see" the material as flat and will flatten onto the material at
15 that location. Conversely, cells in contact with a cavity or irregularity from more than one direction or plane will not "see" a flat area and will retain a rounded conformation or even conform to the shape of the cavity or irregularity. Accordingly, material having a surface-like area greater than about 5 microns would not
20 be likely to result in close vascularization. For example, the material shown in Figure 5a which gave a negative response has many cavities and irregularities which are smaller than about 6 um, but it also has leafy-appearing somewhat flat structures onto which macrophage may flatten. Accordingly, in the present
25 invention material must be selected so that it has sufficient irregularities and cavities to prevent substantial numbers of inflammatory cells from flattening. The rounded cell may conform to the cavities and irregularities but will not flatten. Formation of some flattened cells, especially at the "surface" of
30 the implant is often seen and is within the scope of the invention provided that there are not so many flattened cells that the material is walled off by nonvascularized fibroblasts.

- 23 -

Macrophage behavior is not yet fully understood. It is believed that macrophages are activated when they become flat. Upon activation they are believed to secrete factors which signal fibroblasts to form and proliferate. Accordingly, Applicants
5 hypothesize that by utilizing a material whose three dimensional cavities and irregularities prevent the macrophage from flattening, this invention will avoid macrophage activation and consequent formation of the typical foreign body capsule. On the other hand, it may be that rounded macrophages are secreting
10 factors that either stimulate neovascularization directly or interrupt an existing suppression of new vascularization.

The host inflammatory cell response described above for the various materials is generally observed for up to about 12 weeks following implantation. Thereafter, in both the standard foreign
15 body capsule response and in the use of the instant invention, the inflammatory cells gradually diminish leaving either a stable foreign body capsule or, in the instant invention, a stable vascularized bed. The Applicants have observed a stable vascular bed for 1.5 years in subcutaneous implants of 3 μ m Gore® teflon in
20 rats.

When the material utilized has the three dimensional architecture set forth above, a vascularized membrane is achieved. To this end, the endothelial cells that make up the capillary walls are immediately adjacent to or very close to the
25 material-host interface. There are no, or few, intervening macrophages or fibroblasts. Accordingly, molecules coming through the material will be at the surface of an endothelial cell for transportation into the capillaries. For example, molecules secreted by pancreatic islet cells on one side of the material
30 will be available for uptake by capillaries on the other side of the material. Likewise, molecules such as glucose coming from the capillary, will be sensed by islet cells contained within an

- 24 -

implanted chamber made of the material. The resistance to diffusion of such molecules will be related to the distance necessary to traverse the material.

5 Applicants tests of commercially available membranes (Tables 1 - 3) indicate that close vascular structures will likely result with a material having an average nominal pore size in the range of approximately 0.6 to about 20 microns and being composed of strands, fibers, cones, rods, or microglobules with a diameter no greater than approximately 5 microns.

10 Additional tests have shown that when the average aperture size is greater than approximately 40 microns, although vascular structures grow into the cavities of the membranes the capillaries are not in contact with or adjacent to the material but rather typically lie at some distance from the material due to a halo of
15 macrophages and fibroblasts in a connective tissue matrix that surrounds the capillaries as illustrated in Figure 3. Thus, as in the case of a foreign body capsule on the surface of a membrane, the capillaries are separated from the polymer surface by several layers of cells producing the same kind of diffusive resistance
20 encountered in a classical foreign body response.

In contrast to the present invention, in a typical implant, the implant is encapsulated by the foreign body capsule and is typically at the edges of a large cellular avascular space, see Figure 1.

25 The close vascularization of the present invention improves on previous biopolymer implants because the vascular bed is formed immediately adjacent to the material-host interface. As set forth in more detail below, this method of vascularization has a variety of applications. For example, the material can be used in
30 conjunction with an indwelling sensor, an indwelling catheter, and for an immunoisolation container.

- 25 -

Referring now to Figure 7, an immunoisolation membrane 42 is illustrated. As illustrated, the membrane 42 is selected such that it allows macrophages 34 to enter at least some of the cavities 44 of the membrane causing vascular structures 46 to be formed at the host-membrane interface 47. Again, it should be noted that although some vascular structures can be formed within the cavities 44 of the membrane 42, this is not critical to the success of the material or the creation of a vascular bed.

As illustrated, the membrane 42 surrounds at least a portion of a second membrane or layer 50 that defines an immunoisolated interior 52. This interior 52 can include tissue 54 that must be protected from contact by host cells that would reject the implanted cells. For example, allografts or xenografts or in the case of isografts, such as autologous implants of genetically engineered cells, the membrane would need only to prevent passage of cells to prevent movement of the genetically engineered cells, which often contain retroviral vectors, out of the membrane enclosures and into the host tissues. This isolation of graft tissues from host tissue represents a significant advance over previous methods used for autologous transplantation of genetically engineered cells, because it prevents the genetically engineered cells from potentially invading host tissues in an unregulated manner and causing tumors in the host via the retroviral vector.

On the other hand, it is desirable that the second membrane 50 allow for the diffusion of components generated by the tissues 54, for example, insulin from pancreatic islets. Likewise, it is desirable that the second membrane 50 allow nutrients from the host to enter the interior 52 of the implant and nourish the tissue 54. To this end, the second membrane 50 preferably includes pores 56 that allow glucose or other components to diffuse into the first membrane 42 but prevents macrophages 34 and/or humoral factors from entering the second membrane.

- 26 -

Although the device illustrated in Figure 7 includes two membrane layers, it should be noted that other constructions can be utilized. For example, referring to Figure 8, the device includes a single membrane 61 that includes cavities 62 having a gradient of size. The larger outer cavities 62 allow macrophages to enter at least an outer portion 64 of the cavity 62, causing vascularization at the host-membrane interface 65. However, the smaller inner cavities 66 prevent macrophages from entering an inner portion of the membrane and thereby isolating an interior 68 defined by the membrane.

Referring now to Figure 9, an indwelling catheter 70 including an embodiment of the material 72 of the present invention is illustrated. Such a catheter 70 can be, for example, a catheter for continuous ambulatory peritoneal dialysis.

As illustrated, the material 72 covers the wall 74 of the catheter 70 and allows the creation of a vascular bed around the catheter 70. The wall 74 of the catheter 70 is preferably impenetrable to both cells and molecules.

In typical catheter designs, a thick foreign body of nonvascularized collagenous material is produced around the catheter that acts as a conduit for bacteria. In the present invention, vascularization around the catheter prevents tunnel site infections because necrosis of the tissue is prevented and the vascular bed bathes the area with the entire repertoire of blood borne immune cells. In another embodiment, a flange on a catheter would be covered with a vascularizing material, or would be made entirely from the material.

Referring now to Figure 10, a sensor 80 including an embodiment of the material 82 of the present invention is illustrated. Such a sensor 80 can include, for example, a glucose sensor for monitoring glucose levels in diabetics. As illustrated, the material 82 covers a body 84 which contains an electrode 85 of the sensor 80 and causes a vascular bed 86 to be created around the

- 27 -

sensor 80. The creation of the vascular bed circumvents the problem of foreign body occlusion typically encountered with indwelling sensors.

5 The vascular response is believed to be unrelated to the composition of the material. This is illustrated by the above examples wherein similar responses of the tissue were found with respect to hydrophilic (cellulose) and hydrophobic (teflon) materials. Therefore, the inventors believe that the material can be constructed from a variety of polymers including, inter alia,
10 polyethylene, polypropylene, teflon, cellulose acetate, cellulose nitrate, polycarbonate, polyester, nylon, polyester, polysulfone, mixed esters of cellulose polyvinylidene difluoride, silicone, and polyacrylonitrile. Known biocompatible medical implants are composed of ceramics and metals. Assuming these materials could
15 be manipulated to provide the three dimensional structures described herein, they would also be useful in the present invention.

It should be understood that various changes and modifications to the presently preferred embodiments described herein will be
20 apparent to those skilled in the art. Such changes and modifications can be made without departing from the spirit and scope of the present invention and without diminishing its attendant advantages. It is therefore intended that such changes and modifications be covered by the appended claims.

25

30

- 28 -

CLAIMS

1. A device for implantation in a host having a material at an interface between the host and the device, said material having a conformation which results in growth of vascular structures by the host close to the interface.

2. The device of Claim 1 where said host forms a standard three layer foreign body response and where said conformation results in the formation of vascular structures in the first and second layers of the host foreign body response adjacent to the material.

3. The device of Claim 1 where the conformation of the material is determined by interconnected strands forming frames having two dimensional apertures and said frames forming interconnected three dimensional cavities, where

(a) said strands are three dimensional having one dimension larger than the other two and for the majority of said strands neither of the smaller dimensions exceeds about 5 microns, and

(b) where said apertures have average dimensions no smaller than about 0.6 microns and no larger than about 20 microns.

4. The device of Claim 1 where the material is conformed so that at least some host inflammatory cells that contact the material do not flatten.

5. The device of Claim 4 where the conformation of the material includes three dimensional cavities and irregularities so that host inflammatory cells in contact with the cavities and irregularities can conform to and enter the cavities and irregularities, and do not flatten.

- 29 -

6. The device of Claim 1 where vascular structures grow to within about one cell layer of the material.

7. The device of Claim 1 where the vascular structures grow close enough to the material to permit diffusion of molecules from the vascular structures to the interface.

8. The device of Claim 1 where
(a) the device forms a chamber adapted to contain living cells, and
(b) where the vascular structures grow close enough to the material to permit diffusion of molecules from the vascular structures into the chamber, and
(c) where said diffusion is rapid enough to sustain said living cells.

9. The device of Claim 1 where the material is selected from the group consisting of:

- 1) Millipore® Mixed Esters Cellulose, membrane pore size 1.2;
- 2) Millipore® Mixed Esters Cellulose, membrane pore size 8.0;
- 3) Satorious®, Cellulose Acetate, membrane pore size 0.8;
- 4) Satorious®, Cellulose Acetate, membrane pore size 1.2;
- 5) Satorious®, Cellulose Acetate, membrane pore size 3.0;
- 6) Satorious®, Cellulose Acetate, membrane pore size 5.0;
- 7) Satorious®, Cellulose Acetate, membrane pore size 8.0;
- 8) Gore®, PTFE/Polyester, membrane pore size 1.0;
- 9) Gore®, PTFE/Polyester, membrane pore size 3.0;
- 10) Gore®, PTFE/Polyester, membrane pore size 5.0;
- 11) Gore®, PTFE/Polyester, membrane pore size 10-15;
- 12) Gore®, PTFE/Polypropylene, membrane pore size 3.0;
- 13) Gelman®, Versapore®, membrane pore size 0.8;
- 14) Gelman®, Versapore®, membrane pore size 1.2;
- 15) Gelman®, Versapore®, membrane pore size 3.0; and
- 16) Gelman®, Versapore®, membrane pore size 5.0;

- 30 -

10. The device of Claim 1 where the material is impermeable to immunogenic factors.

5 11. A device for implantation in a host having a first material at an interface between the host and the device, said first material having a conformation which results in growth of vascular structures by the host close to the interface, the device further having a second material underlying the first material, the second material being impermeable to immunogenic factors.

10 12. The device of Claim 11 defining a chamber whose interior is adapted to hold living cells, the first and second materials being permeable to nutrients present in the vascular structures.

15 13. The device of Claim 1 where the device is an indwelling catheter.

20 14. The device of Claim 1 where the device is an indwelling sensor and where the material is permeable to an analyte in the host detectable by the sensor.

15. The device of Claim 1 where the device is a breast prosthesis.

25 16. An implanted device and the localized host response to the implanted device comprising:

- (a) the device of Claim 1 implanted; and
- (b) host vascular structures within about one cell layer of the device.

30 17. A method comprising:

- (a) implanting a device having a material at an interface between the host and the device; and

- 31 -

(b) said material having a conformation which results in growth of vascular structures by the host close to the interface.

5 18. The method of Claim 17 where said host forms a standard three layer foreign body response and where said conformation results in the formation of vascular structures in the first and second layers of the host foreign body response adjacent to the material.

10 19. The method of Claim 17 where the conformation of the material is determined by interconnected strands forming frames having two dimensional apertures and said frames forming interconnected three dimensional cavities, where

15 (a) said strands are three dimensional having one dimension larger than the other two and for the majority of said strands neither of the smaller dimensions exceeds about 5 microns, and

(b) where said apertures have average dimensions no smaller than about 0.6 microns and no larger than about 20 microns.

20

20. The method of Claim 17 where the material is conformed so that at least some host inflammatory cells that contact the material do not flatten.

25 21. The method of Claim 20 where the conformation of the material includes three dimensional cavities and irregularities so that at least some host inflammatory cells in contact with the cavities and irregularities can conform to and enter the cavities and irregularities, and do not flatten.

30

22. The method of Claim 17 where vascular structures grow to within about one cell layer of the material.

- 32 -

23. The method of Claim 17 where the vascular structures grow close enough to the material to permit diffusion of molecules from the vascular structures to the interface.

5 24. The method of Claim 17 where

(a) the device forms a chamber adapted to contain living cells, and

(b) where the vascular structures grow close enough to the material to permit diffusion of molecules from the vascular
10 structures into the chamber, and

(c) where said diffusion is rapid enough to sustain said living cells.

15 25. The method of Claim 17 where the material is selected from the group consisting of:

- 1) Millipore® Mixed Esters Cellulose, membrane pore size 1.2;
- 2) Millipore® Mixed Esters Cellulose, membrane pore size 8.0;
- 3) Satorious®, Cellulose Acetate, membrane pore size 0.8;
- 4) Satorious®, Cellulose Acetate, membrane pore size 1.2;
- 20 5) Satorious®, Cellulose Acetate, membrane pore size 3.0;
- 6) Satorious®, Cellulose Acetate, membrane pore size 5.0;
- 7) Satorious®, Cellulose Acetate, membrane pore size 8.0;
- 8) Gore®, PTFE/Polyester, membrane pore size 1.0;
- 9) Gore®, PTFE/Polyester, membrane pore size 3.0;
- 25 10) Gore®, PTFE/Polyester, membrane pore size 5.0;
- 11) Gore®, PTFE/Polyester, membrane pore size 10-15;
- 12) Gore®, PTFE/Polypropylene, membrane pore size 3.0;
- 13) Gelman®, Versapore®, membrane pore size 0.8;
- 14) Gelman®, Versapore®, membrane pore size 1.2;
- 30 15) Gelman®, Versapore®, membrane pore size 3.0; and
- 16) Gelman®, Versapore®, membrane pore size 5.0;

- 33 -

26. The method of Claim 17 where the material is impermeable to immunogenic factors.

27. A method comprising implanting in a host:

5 (a) a device having a first material at an interface between the host and the device,

(b) said first material having a conformation which induces growth of vascular structures by the host close to the interface,

10 (c) the device further having a second material underlying the first material; and

(d) the second material being impermeable to immunogenic factors.

15 28. The method of Claim 27 where the device is a chamber whose interior is adapted to hold living cells, the first and second materials being permeable to nutrients present in the vascular structures.

20 29. The method of Claim 17 where the device is an indwelling catheter.

25 30. The method of Claim 17 where the device is an indwelling sensor and where the material is permeable to an analyte in the host detectable by the sensor.

31. The method of Claim 17 where the device is a breast prosthesis.

30 32. An immunoisolation container comprising:

(a) a first membrane having pores, at least some of the pores having a sufficient size and structure to allow macrophages to enter the pores and cause at least some vascular structures to contact the membrane; and

- 34 -

(b) a second porous membrane, the pores of the second membrane being sufficiently small to prevent macrophages from entering an interior of the container.

5 33. The container of Claim 32 wherein the first membrane has a nominal pore size of approximately 0.6 microns to about 20 microns.

10 34. The container of Claim 32 wherein at least some of the pores of the first membrane have a sufficient size to allow at least some vascular structures to be created within the pores.

15 35. The container of Claim 32 wherein the first membrane includes at least approximately 50 percent of the pores having a size of approximately 0.6 microns to about 20 microns.

 36. The container of Claim 32 wherein a majority of structures that delimit the pores of the first membrane have a diameter of less than approximately 5 microns.

20 37. The container of Claim 32 wherein the second membrane includes pores that are sufficiently small to prevent any cells from entering or leaving the interior of the container.

25

30

FIG. 1a




FIG. 1b




FIG. 2a







FIG. 2b




3 / 8

FIG. 3**FIG. 7**


4 / 8

FIG. 4a




15KV X2000 0912 10.0µM MMTc

FIG. 4b




15KV X2000 0405 10.0µM MMTc

FIG. 5a



15KV X2000 0501 10.0μ MMTc

FIG. 5b



15KV X2000 0522 10.0μ MMTc

FIG. 6







FIG. 8




8 / 8

FIG. 9**FIG. 10**

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 91/07486

I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all) ⁶		
According to International Patent Classification (IPC) or to both National Classification and IPC		
Int.Cl. 5 A61F2/00; A61F2/02		
II. FIELDS SEARCHED		
Minimum Documentation Searched?		
Classification System	Classification Symbols	
Int.Cl. 5	A61F ; A61M	
Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched ⁸		
III. DOCUMENTS CONSIDERED TO BE RELEVANT⁹		
Category ^o	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³
X	US,A,4 374 669 (MAC GREGOR) 22 February 1983 see column 3, line 24 - line 55 ---	1-11
X	EP,A,0 277 678 (STICHTING SCIENCE PARK GRONINGEN) 10 August 1988	1-8
Y	see the whole document ---	11-24, 26-28
X	EP,A,0 188 309 (CONNAUGHT LABORATORIES LTD.) 23 July 1986	1-8
Y	see page 2, line 27 - page 3, line 27 see page 10, line 5 - line 34 ---	11-24, 26-28
X	WO,A,9 000 888 (THE COOPER COMPANIES INC.) 8 February 1990	1
Y	see page 9, line 11 - page 11, line 15; figures ---	11,15, 27,31-37
-/-		
^o Special categories of cited documents : ¹⁰ "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. "&" document member of the same patent family		
IV. CERTIFICATION		
Date of the Actual Completion of the International Search	Date of Mailing of this International Search Report	
28 FEBRUARY 1992	09.03.92	
International Searching Authority	Signature of Authorized Officer	
EUROPEAN PATENT OFFICE	SANCHEZ Y SANCHEZ J. 	

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)		
Category °	Citation of Document, with indication, where appropriate, of the relevant passages	Relevant to Claim No.
Y	EP,A,0 232 543 (SUMIMOTO) 19 August 1987 see abstract; claims ---	11,15, 27,31-37
X	EP,A,0 359 575 (CLEMSON UNIVERSITY) 21 March 1990 cited in the application see the whole document ---	1-37
A	GB,A,2 185 408 (RHODE ISLAND HOSPITAL) 22 July 1987 ---	

**ANNEX TO THE INTERNATIONAL SEARCH REPORT
ON INTERNATIONAL PATENT APPLICATION NO.**

US 9107486
SA 53797

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report. The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information. 28/02/92

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US-A-4374669	22-02-83	CA-A- 1069252	08-01-80
		DE-A, B, C 2620631	11-11-76
		FR-A, B 2310122	03-12-76
		JP-A- 52001995	08-01-77
		US-A- 4280514	28-07-81
		US-A- 4355426	26-10-82
		US-A- 4459252	10-07-84
		US-A- 4458366	10-07-84
		US-A- 4627836	09-12-86
		US-A- 4101984	25-07-78
		US-A- 4934381	19-06-90
		US-A- 4281669	04-08-81
		US-A- 4936317	26-06-90
		CA-A- 1105652	28-07-81
		CA-A- 1068052	18-12-79
		CA-A- 1100191	28-04-81
		CA-A- 1115456	05-01-82
EP-A-0277678	10-08-88	NL-A- 8700113	16-08-88
		AU-A- 1037688	21-07-88
		JP-A- 63272355	09-11-88
EP-A-0188309	23-07-86	CA-A- 1258429	15-08-89
		JP-A- 61209586	17-09-86
WO-A-9000888	08-02-90	ES-A- 2010327	01-11-89
EP-A-0232543	19-08-87	JP-A- 62152470	07-07-87
EP-A-0359575	21-03-90	US-A- 5011494	30-04-91
GB-A-2185408	22-07-87	US-A- 4699141	13-10-87
		CA-A- 1272422	07-08-90
		DE-A, C 3701148	23-07-87
		FR-A- 2592785	17-07-87
		JP-A- 62211062	17-09-87
		NL-A- 8700097	17-08-87